Eugene Zhu

562 total citations
11 papers, 301 citations indexed

About

Eugene Zhu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Eugene Zhu has authored 11 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Eugene Zhu's work include Prostate Cancer Treatment and Research (5 papers), PARP inhibition in cancer therapy (5 papers) and Lymphoma Diagnosis and Treatment (4 papers). Eugene Zhu is often cited by papers focused on Prostate Cancer Treatment and Research (5 papers), PARP inhibition in cancer therapy (5 papers) and Lymphoma Diagnosis and Treatment (4 papers). Eugene Zhu collaborates with scholars based in United States, Canada and France. Eugene Zhu's co-authors include Christopher Enny, Evgenii A. Osmanov, Helgi van de Velde, Fritz Offner, Deborah Ricci, Aleksandra Rizo, Shalini Chaturvedi, João Raposo, Olga Samoilova and Hyeon‐Seok Eom and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Eugene Zhu

11 papers receiving 299 citations

Peers

Eugene Zhu

ONCOL

PFM

GENET

HEMAT

Fatime Krasniqi Switzerland

Vít Campr Czechia

Diana Libster Israel

Roshanak Bob Germany

Sandra P. Susanibar-Adaniya United States

Maria Cristina Pirosa Switzerland

Jordina Rovira Spain

Rishu Agarwal Australia

Evgenii A. Osmanov Russia

Sarah C. Rutherford United States

Fatime Krasniqi Switzerland

Eugene Zhu

154 ×0.9

ONCOL

202 ×1.3

PFM

69 ×0.6

GENET

109 ×1.3

119 ×2.3

HEMAT

Citations per year, relative to Eugene Zhu Eugene Zhu (= 1×) peers Fatime Krasniqi

Countries citing papers authored by Eugene Zhu

Since Specialization

Citations

This map shows the geographic impact of Eugene Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eugene Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eugene Zhu more than expected).

Fields of papers citing papers by Eugene Zhu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eugene Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eugene Zhu. The network helps show where Eugene Zhu may publish in the future.

Co-authorship network of co-authors of Eugene Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Eugene Zhu. A scholar is included among the top collaborators of Eugene Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eugene Zhu. Eugene Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Urtishak, Karen, Gerhardt Attard, Tokuwa Kanno, et al.. (2022). Abstract 4133: High prevalence and heterogeneity of emergence of BRCA reversion mutations at progression on niraparib treatment in BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) patients. Cancer Research. 82(12_Supplement). 4133–4133. 2 indexed citations

Saad, Fred, Kim N., Neal D. Shore, et al.. (2021). Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Cancer Chemotherapy and Pharmacology. 88(1). 25–37. 23 indexed citations

Kuykendall, Andrew, Libo Sun, John Mascarenhas, et al.. (2021). Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data. Annals of Hematology. 101(1). 139–146. 18 indexed citations

Saad, Fred, Kim N., Neal D. Shore, et al.. (2020). Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(6_suppl). 122–122. 1 indexed citations

Smith, Matthew R., Karim Fizazi, Shahneen Sandhu, et al.. (2020). Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.. Journal of Clinical Oncology. 38(6_suppl). 118–118. 17 indexed citations

Subudhi, Sumit K., Ana M. Aparicio, Amado J. Zurita, et al.. (2019). A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350).. Journal of Clinical Oncology. 37(15_suppl). TPS5087–TPS5087. 4 indexed citations

Mascarenhas, John, Rami S. Komrokji, Michèle Cavo, et al.. (2018). Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels. Blood. 132(Supplement 1). 685–685. 29 indexed citations

Offner, Fritz, Olga Samoilova, Evgenii A. Osmanov, et al.. (2015). Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 126(16). 1893–1901. 98 indexed citations

Zinzani, Pier Luigi, Nuriet K. Khuageva, Huaqing Wang, et al.. (2012). Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. Journal of Hematology & Oncology. 5(1). 67–67. 17 indexed citations

10.

Coiffier, Bertrand, Evgenii A. Osmanov, Xiaonan Hong, et al.. (2011). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology. 12(8). 773–784. 81 indexed citations

11.

Coiffier, Bertrand, Evgenii A. Osmanov, Xiaonan Hong, et al.. (2010). A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma. Blood. 116(21). 857–857. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact